Equity (Tables)
|
12 Months Ended |
Dec. 31, 2024 |
Equity |
|
Schedule of common stock outstanding |
A. | Share capital (in thousands of shares of NIS 5 par value per share) |
| | | | | | | Ordinary shares | | | 2023 | | 2024 | Issued as of January 1 | | 258,564 | | 235,597 | Repurchase of treasury shares | | (32,016) | | (26,043) | Exercise of warrants during the period | | 3,559 | | 3 | Exercise of share options and RSUs during the period | | 5,490 | | 6,220 | Issued and paid-in share capital as of December 31 | | 235,597 | | 215,777 |
|
Schedule of stock options activity |
| | | | | | | | | | | | | Weighted | | | | | | | | average | | | | | | Number | | exercise | | Weighted average | | | of options | | price | | intrinsic value | Outstanding on December 31, 2023 | | 4,039,537 | | $ | 2.02 | | $ | 1.00 | Granted | | — | | | — | | | — | Exercised | | (856,812) | | | 0.74 | | | 1.70 | Forfeited and expired | | (555,630) | | | 2.64 | | | 1.16 | | | | | | | | | | Outstanding on December 31, 2024 | | 2,627,095 | | | 2.30 | | | 0.80 | Exercisable as of December 31, 2024 | | 1,421,261 | | | 2.38 | | | 0.79 |
|
Schedule of valuation assumptions of the options granted |
The table below summarizes the assumptions used in determining the fair value of the options granted in 2022-2023: | | | Range of expected share price volatility | | 103.2%-121.85% | Range of estimated life (years) | | 4.5-8 | Range of weighted average of risk-free interest rate | | 4.33%-4.5% | Expected dividend yield | | — |
|
Schedule of RSUs activity |
| | | | | | | | | | Weighted | | | | | average | | | Number of Units | | grant price | Outstanding on December 31, 2023 | | 12,468,235 | | $ | 3.33 | Granted | | 5,817,136 | | | 2.40 | Exercised | | (4,869,624) | | | 3.53 | Forfeited | | (2,522,359) | | | 3.32 | | | | | | | Outstanding on December 31, 2024 | | 10,893,388 | | $ | 2.75 |
|
Schedule of warrants activity and related information |
| | | | | | | | | | | | | | | Weighted | | | | | | | | average | | | | | Weighted | | remaining | | | | | average | | contractual | | | | | exercise | | life (in | | | Warrants | | price | | years) | Outstanding on December 31, 2023 | | 36,465,771 | | $ | 6.30 | | 1.18 | Granted | | — | | | | | | Exercised | | (41,540) | | | 2.50 | | 0.33 | Expired | | (1,606,605) | | | 7.48 | | — | | | | | | | | | Outstanding and exercisable as of December 31, 2024 | | 34,817,626 | | $ | 6.26 | | 1.24 |
|
Schedule of stock-based compensation expense |
| | | | | | | | | | For the year ended December 31 | | | 2022 | | 2023 | | 2024 | | | | | | | | | Cost of revenues | | $ | 666 | | 811 | | 938 | Research and development expenses | | | 12,708 | | 10,297 | | 6,079 | Sales and marketing expenses | | | 6,564 | | 4,891 | | 1,649 | General and administrative expenses | | | 11,276 | | 6,111 | | 7,055 | | | $ | 31,214 | | 22,110 | | 15,721 |
|